Loading...
Loading...
J.P. Morgan Chase & Co. is out with a research report on Mako Surgical
MAKO and it is raising its price target to $37 from $28, but is keeping its Neutral rating after it reported earnings.
In a note to clients, J.P. Morgan Chase & Co. writes, "Mako reported 3Q results Wednesday night, with sales of $20.0M topping Street consensus by $600k. Mako sold a total of 11 systems in the quarter, which was one system light of both our estimate and Street consensus. The company reported a net loss of $0.24/share, which was $0.02 below the Street as well as our forecast. Despite underwhelming 3Q results, key updates including: (1) two systems placed at HSS; and (2) a faster trajectory of hip upgrades should give investors increased confidence around Mako's 2012 outlook heading into year-end."
Shares of MAKO lost $2.51 yesterday to close at $33.34, a loss of 7%.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentJ.P. Morgan Chase & Co.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in